XRAY: Director Mazelsky Acquires 2,638 Phantom Stock Shares May 19, 2026

Insider trading can reveal what company leaders really think about the future. When executives buy shares or receive equity awards, it often signals confidence in the business. Today we’re examining a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), where a director received a substantial phantom stock award. This acquisition shows continued executive engagement with the company’s compensation structure and long-term value creation strategy.

Director Phantom Stock Award Details

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA, acquired 2,638 phantom stock units through the company’s Directors’ Deferred Compensation (DDC) plan on December 31, 2025. This award was filed with the SEC on January 2, 2026. Phantom stock represents a contractual right to receive cash or shares equal to the stock’s value at a future date, making it a valuable long-term incentive tool.

The SEC filing shows Mazelsky now holds 14,382 phantom stock units total. This represents meaningful accumulated equity in the deferred compensation program. The award type is classified as an A-Award, indicating a grant or acquisition of securities rather than a sale or disposition.

What Phantom Stock Means for Directors

Phantom stock is a non-dilutive equity incentive that tracks real stock performance without issuing actual shares. Directors receive these awards as part of their compensation package to align their interests with shareholders. When the phantom stock vests or is settled, directors receive cash or shares equivalent to the underlying stock value.

This compensation structure encourages long-term thinking among board members. Mazelsky’s growing phantom stock position suggests he remains committed to DENTSPLY SIRONA’s strategic direction. The deferred compensation plan allows directors to build wealth while maintaining governance independence.

Insider Activity Signal and Market Context

This transaction represents a pure acquisition with no offsetting sales, indicating positive insider sentiment. Directors typically don’t sell phantom stock unless they need liquidity, so accumulation signals confidence. Mazelsky’s continued participation in the DDC program shows he values the company’s long-term prospects.

DENTSPLY SIRONA trades with a market cap of $1.97 billion and carries a Meyka Grade of B, reflecting solid fundamentals and sector positioning. The company operates in dental equipment and technology, a stable healthcare subsector. This insider award reinforces management’s belief in sustainable value creation.

Form 4 Filing Explained

The transaction was reported on Form 4, the standard SEC document for insider trades and equity awards. Form 4 filings must be submitted within two business days of the transaction date. This transparency requirement helps investors track executive and director activity in real time.

The filing clearly identifies the transaction type (A-Award), the security (phantom stock DDC), and the quantity acquired (2,638 units). No price per share is listed because phantom stock awards are typically granted at no cost to the recipient. The filing provides a complete audit trail of insider compensation decisions.

Final Thoughts

Jonathan Mazelsky’s acquisition of 2,638 phantom stock units demonstrates continued director engagement with DENTSPLY SIRONA’s long-term incentive structure. The growing phantom stock position (now 14,382 units) reflects confidence in the company’s strategic direction and value creation potential. This insider activity, combined with XRAY’s solid B-grade fundamentals, suggests stable leadership commitment to shareholder interests. The transaction reinforces that board members remain aligned with company performance through meaningful deferred compensation holdings.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.